CYTARABINE 100MG-1ML VIAL 100 mg/ml Solution for injection 5ml Vial 5pcs
Product Overview
CYTARABINE 100MG-1ML VIAL is an essential antineoplastic agent, presented as a 100 mg/ml solution for injection.
This critical medication is widely utilized in the treatment of various aggressive cancers, predominantly leukemias and lymphomas.
As a cornerstone of many chemotherapy protocols, Cytarabine functions by specifically interfering with DNA synthesis, thereby effectively inhibiting the rapid growth and proliferation of malignant cancer cells.
For comprehensive professional medical referencing and detailed usage instructions, healthcare practitioners often consult authoritative pharmaceutical product databases. Reputable e-commerce pharmacies such as Nahdi Online, , or also provide extensive product information and professional guidance for such specialized medical products.
Key Benefits
- Effective in treating acute myeloid leukemia (AML), a severe blood cancer.
- Crucially used for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in its blast phase.
- Plays a significant role in the therapeutic management of certain non-Hodgkin's lymphomas.
- Its primary mechanism involves disrupting DNA synthesis, which is vital for rapidly dividing cancer cells, leading to their inhibition.
How to Use
Cytarabine is a potent and highly specialized chemotherapy agent that demands strict administration by a qualified healthcare professional.
The specific method of administration, precise dosage, and overall duration of treatment are meticulously determined by the treating physician.
- CYTARABINE 100MG-1ML VIAL is prepared and administered via intravenous (IV), subcutaneous (SC), or intrathecal (IT) routes.
- The optimal route and tailored dosage schedule will be precisely established by the physician, based on individual patient needs and cancer type.
- Continuous and careful monitoring of blood counts, along with other vital signs, is absolutely essential throughout the entire treatment period to ensure patient safety and efficacy.
- Dosage adjustments may be necessary, contingent upon the patient's individual tolerance to the medication and their therapeutic response.
Caution & Warnings
Severe Myelosuppression: Cytarabine carries a significant risk of severe, potentially life-threatening bone marrow depression. This can manifest as severe anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count). Frequent and rigorous monitoring of blood counts is mandatory during treatment.
Neurotoxicity: Administration of high doses of Cytarabine can lead to severe neurological toxicities. These may include, but are not limited to, cerebral and cerebellar dysfunction, which can impact coordination and cognitive function.
Gastrointestinal Toxicity: Common adverse gastrointestinal effects include nausea, vomiting, diarrhea, and stomatitis (inflammation of the mouth and lips). Supportive care is often required to manage these symptoms.
Hepatic and Renal Impairment: Extreme caution is advised when administering Cytarabine to patients with pre-existing liver or kidney dysfunction. Dosage modifications and careful monitoring of organ function may be critically required.
Pulmonary Toxicity: Although rare, serious pulmonary complications such as acute respiratory distress syndrome (ARDS) and pulmonary edema can occur. Patients should be monitored for respiratory symptoms.
Pregnancy and Lactation: Cytarabine is classified as Pregnancy Category D, indicating a clear risk to the human fetus. It is strictly contraindicated in pregnant women due to potential fetal harm. Furthermore, it is strongly not recommended during breastfeeding due to the risk of excretion into breast milk and potential harm to the infant.
Immunosuppression: Patients undergoing Cytarabine therapy experience significant immunosuppression, rendering them highly susceptible to severe and opportunistic infections. Prophylactic measures and prompt management of infections are crucial.
Drug Interactions: Potential for significant interactions exists with other myelosuppressive agents, leading to additive bone marrow suppression. Interactions with medications like digoxin and gentamicin have also been reported. It is imperative to always inform your physician about all prescription, over-the-counter medications, and supplements you are currently taking.
Extravasation: Utmost care must be taken to prevent extravasation (leakage of the drug into surrounding tissue) during intravenous administration, as it can cause localized tissue damage, necrosis, and severe pain.
Ingredients
Active Ingredient: Cytarabine 100 mg/ml.
Product Details
- Product Name: CYTARABINE 100MG-1ML VIAL
- Strength: 100 mg/ml
- Form: Solution for injection
- Package Size: 5ml Vial, 5 pcs per pack
- Therapeutic Class: Antineoplastic Agent (Chemotherapy)
- Administration Route: Parenteral (IV, SC, IT)
| Gtin | 14-5287-20 |
|---|---|
| Recommended Sale Price | 302.85 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | CYTARABINE |
| SFDA Reg. No | 14-5287-20 |
| IBC | 14-5287-20 |
| Drug Type | Prescription |
| Scientific Name | Cytarabine |
| Strength | 100 mg/ml |
| Strength Unit | mg/ml |
| Form | Solution for injection |
| Admin Route | Parenteral (IV, SC, IT) |
| Size | 5ml |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 5 vials x 5ml |
| Storage conditions | Store at room temperature (20-25°C). Protect from light. Do not freeze. |
| Refrigerator Storage | No |
